[The role of nicergoline in the symptomatic treatment of arterial hypertension and chronic cerebrovascular insufficiency. A study on 359 observations (author's transl)].
An examination was carried out on the efficacy of 10-methoxy-1,6-diemethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) on the symptoms of functional side effects of arterial hypertension and chronic circulatory insufficiency as regards the psychomotoric activity and the relational activity; 359 patients suffering from crebrovascular insufficiency were included in the study. The compound was applied in a daily dose of 10 mg i. m. for 5 days and then in a daily dose of 15 mg orally for 1 month. In the entire symptom complex of cerebro-vascular insufficiency a positive effect of nicergoline could be observed; the results of all clinical criteria and their therapeutic relevance are discussed.
D000328:Adult; D000368:Aged; D002561:Cerebrovascular Disorders / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009530:Nicergoline / Q000627:therapeutic use*
D004873:Ergolines; D009530:Nicergoline
Bedeutung von Nicergolin bei der symptomatischen Behandlung des arteriellen Hochdrucks und der chronischen, zerebro-vaskulären Insuffizienz. Studie an 359 Beobachtungen.